AbbVie's Humira nabs orphan status in skin disease; GSK-backed poll boosts case for meningitis vaccines;

> AbbVie's ($ABBV) top-selling anti-inflammatory therapy Humira won an FDA orphan designation in the rare skin disease hidradenitis, making the drug eligible for 7 years of exclusivity in that indication. Report

> A new U.S. poll found that 83% of parents want their teens and young adults to be vaccinated against meningococcal disease; the survey was sponsored by GlaxoSmithKline ($GSK), which markets the men B shot Menhibrix. Release

> A generics maker is suing the FDA after the agency declared that its version of the Johnson & Johnson ($JNJ) ADHD med Concerta wasn't bioequivalent to the brand, nixing the copycat med's automatic substitution at pharmacies. Report

> The first set of American Urological Association guidelines for Peyronie's disease, in which scar tissue builds up in the penis, recommends Endo's ($ENDP) Xiaflex as a treatment option. Release

> Makovsky's health practice director Gil Bashe jumped ship to join rival PR firm Finn Partners, where he'll focus on growing the firm's business in biopharma. Report

> The health-focused communications agency KYNE recruited Novartis ($NVS) vet Maureen Byrne to head up its New York office. Report

And Finally... Merck KGaA could have trouble hitting healthcare heights. Report (sub. req.)